Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fevipiprant for nasal polyposis with concomitant asthma
NL-OMON48110Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of fevipiprant in chronic rhinosinusitis with nasal polyps (CRSwNP) and asthma (3 arms), sponsored by Novartis. Primary endpoint: Change from baseline in nasal polyp size at Week 16. Started Apr 2019; status: active, not recruiting.
02
Drugs
fevipiprant
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)asthma
Beyond the preview
Go deeper on NL-OMON48110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48110.